Drugs / LiteVax Adjuvant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06986239 | Jul 2025 → Apr 2026 overdue | — | LiteVax BV | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06294262 | Jan → Sep 2024 | vaccinia | LiteVax BV | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LiteVax Adjuvant | “Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant” NCT06294262 ↗1“1 mg of LiteVax Adjuvant (LVA)” NCT06986239 ↗ |
| Known as | LVA | “1 mg of LiteVax Adjuvant (LVA)” NCT06986239 ↗ |
| Route | Intramuscular | “Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant” NCT06294262 ↗ |